Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

The Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research grant (R33 - Clinical Trials Not Allowed) is a funding opportunity that seeks applications to advance technologies and platforms that will enhance predictive, diagnostic, and therapeutic products for disorders and diseases related to the heart, lung, blood, and sleep (HLBS).

This specific Funding Opportunity Announcement (FOA) is focused on inviting R33 applications that already have significant feasibility gaps for the enabling technology or transformative platform addressed with the help of preliminary data. However, these technologies and platforms still need further development and decisive validation to foster their demonstration, utilisation, and adoption downstream.

Ideal applications should present the potential to expedite and/or revolutionise areas such as early detection, screening, model development, clinical diagnosis, treatment, control, prevention, or epidemiology of HLBS-related diseases and disorders. Applications centered on the usage of existing technologies where the uniqueness lies in the biological or clinical target/question being addressed are not appropriate for this call and will not be considered.

This FOA is part of the broader NHLBI Catalyze program, aimed at progressing projects to the stage where they are eligible for inclusion in the NHLBI Catalyze Product Definition or Preclinical Funding Opportunity Announcements.